Creator-led campaign featuring a “Hot Take Hotline” aims to spark conversation around an inclusive future for AI
NEW YORK, Oct. 14, 2025 /PRNewswire/ — Girls Who Code is giving the microphone to girls and nonbinary…
Creator-led campaign featuring a “Hot Take Hotline” aims to spark conversation around an inclusive future for AI
NEW YORK, Oct. 14, 2025 /PRNewswire/ — Girls Who Code is giving the microphone to girls and nonbinary…
Jerome Powell, chairman of the US Federal Reserve, during a news conference following a Federal Open Market Committee (FOMC) meeting in Washington, DC, US, on Wednesday, Sept. 17, 2025.
Kent Nishimura | Bloomberg | Getty Images
Federal Reserve Chair Jerome Powell on Tuesday suggested the central bank is nearing a point where it will stop reducing the size of its bond holdings, but gave no long-run indication of where interest rates are heading.
Speaking to the National Association for Business Economics’ conference in Philadelphia, Powell provided a dissertation on where the Fed stands with “quantitative tightening,” or the effort to reduce the more than $6 trillion of securities it holds on its balance sheet.
While he provided no specific date of when the program will cease, he said there are indications that the Fed is nearing its goal of “ample” reserves available for banks.
“Our long-stated plan is to stop balance sheet runoff when reserves are somewhat above the level we judge consistent with ample reserve conditions,” Powell said in prepared remarks. “We may approach that point in coming months, and we are closely monitoring a wide range of indicators to inform this decision.”
Though balance sheet questions are in the weeds for monetary policy, they matter to financial markets.
When financial conditions are tight, the Fed aims for “abundant” reserves so that banks have access to liquidity and can keep the economy running. As conditions change, the Fed aims for “ample” reserves, a step down that prevents too much capital from sloshing around the system.
During the Covid pandemic, the central bank had aggressively purchased Treasurys and mortgage-backed securities, swelling the balance sheet to close to $9 trillion.
Since mid-2022, the Fed has been gradually allowing maturing proceeds of those securities to roll off the balance sheet, effectively tightening one leg of monetary policy. The question had been how far the Fed needed to go, and Powell’s comments indicate that the end is close.
He noted that “some signs have begun to emerge that liquidity conditions are gradually tightening” and could be signaling that reducing reserves further would hinder growth. However, he also said the Fed has no plans to go back to its pre-Covid balance sheet size, which was closer to $4 trillion.
On a related matter, Powell noted concerns over the Fed continuing to pay interest on bank reserves.
The Fed normally remits interest it earns from its holdings to the Treasury general fund. However, because it had to raise interest rates so quickly to control inflation, it has seen operating losses. Congressional leaders such as Sen. Ted Cruz, (R-Texas) have suggested terminating the payments on reserves.
However, Powell said that would be a mistake and would hinder the Fed’s ability to carry out policy.
“While our net interest income has temporarily been negative due to the rapid rise in policy rates to control inflation, this is highly unusual. Our net income will soon turn positive again, as it typically has been throughout our history,” he said. “If our ability to pay interest on reserves and other liabilities were eliminated, the Fed would lose control over rates.”
On the larger issue of interest rates, Powell generally stuck to the recent script, namely that policymakers are concerned that the labor market is tightening and skewing the balance of risks between employment and inflation.
“While the unemployment rate remained low through August, payroll gains have slowed sharply, likely in part due to a decline in labor force growth due to lower immigration and labor force participation,” he said. “In this less dynamic and somewhat softer labor market, the downside risks to employment appear to have risen.”
Powell noted that the Federal Open Market Committee responded in September to the situation with a quarter percentage point reduction on the federal funds rate. While markets strongly expect two more cuts this year, and several Fed officials recently have endorsed that view, Powell was noncommittal.
“There is no risk-free path for policy as we navigate the tension between our employment and inflation goals,” he said.
The Fed has been hampered somewhat by the government shutdown and the impact it has had on economic data releases. Policymakers rely on metrics like the nonfarm payrolls report, retail sales and various price indexes to make their decisions.
Powell said the Fed is continuing to analyze conditions based on the data that is available.
“Based on the data that we do have, it is fair to say that the outlook for employment and inflation does not appear to have changed much since our September meeting four weeks ago. “Data available prior to the shutdown, however, show that growth in economic activity may be on a somewhat firmer trajectory than expected.”
The Bureau of Labor Statistics has said it has called workers back to prepare the monthly consumer price index report, which will be released next week.
Powell said available data has showed that goods prices have increased, largely a function of tariffs rather than underlying inflation pressures.
This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation!
The chief interest at Monday’s largely pointless Gaza summit in Sharm el-Sheikh lay in whether Donald Trump insulted or feted his fellow global leaders as they approached the self-styled world’s greatest peacemaker to shake hands and pose for…
A prostate cancer patient has said that he would likely survive the disease had a screening programme been available when he was younger.
Grant…
A train of solar storms is barreling toward Earth, with four coronal mass ejections (CMEs) expected to hit over the next few days. Any potential impact could trigger impressive auroras in northern skies and possibly even at…
Scientists have finally uncovered the exact DNA sequence where human chromosomes fuse to form Robertsonian chromosomes, a mystery that has puzzled researchers for over a century.
Using advanced genome sequencing at the Stowers…
This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation!
The addition of tucatinib (Tukysa) to maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) displayed a statistically significant improvement in progression-free survival (PFS) vs placebo as a first-line treatment for patients with HER2-positive metastatic breast cancer, according to a news release from the drug’s developer, Pfizer Inc.1
The investigational agent was assessed in combination with trastuzumab and pertuzumab across the aforementioned patient population in the
“[HER2-positive] breast cancer is a particularly challenging subtype, with many patients experiencing disease progression despite effective treatments in the first-line setting,” Erika Hamilton, MD, principal investigator of HER2CLIMB-05 and director of Breast Cancer Research at the Sarah Cannon Research Institute (SCRI), stated in the news release on the study findings.1 “The [phase 3] HER2CLIMB-05 results demonstrate that the addition of [tucatinib] to first-line maintenance therapy may further lower the risk of disease progression or death, with a treatment that has a well-established safety profile.”
The double-blind phase 3 trial enrolled patients with HER2-positive metastatic breast cancer following taxane-based induction therapy. Those who completed induction therapy with trastuzumab, pertuzumab, and a taxane with no evidence of disease progression were randomly assigned 1:1 to receive tucatinib (n = 326) or placebo (n = 328) plus trastuzumab and pertuzumab as maintenance.
Patients in both arms received trastuzumab at 6 mg/kg intravenously or 600 mg subcutaneously plus pertuzumab at 420 mg intravenously every 21 days as maintenance therapy.2 Those in the investigational arm received tucatinib at 300 mg orally twice daily every 21 days, with those in the control arm receiving matching placebo.
The primary end point of the trial was investigator-assessed PFS. Secondary end points included overall survival, PFS per blinded independent central review, central nervous system PFS, health-related quality of life, and adverse effects (AEs).2
Warnings and precautions of treatment with tucatinib include severe diarrhea, dehydration, hypotension, acute kidney injury, and death. Additionally, patients may be at risk of hepatotoxicity, including alanine aminotransferase increases, aspartate aminotransferase increases, and bilirubin increases. Furthermore, tucatinib may cause embryo-fetal toxicities among patients who are pregnant or of reproductive potential.
In the phase 3 HER2CLIMB trial (NCT02614794), serious AEs were reported in 26% of the tucatinib arm, the most common of which included diarrhea (4%), vomiting (2.5%), nausea (2%), abdominal pain (2%), and seizure (2%). The most common fatal AEs included sudden death, sepsis, dehydration, and cardiogenic shock.
Dose reductions related to AEs occurred in 21% of patients, the most common of which were hepatotoxicity (8%) and diarrhea (6%).
Currently, tucatinib is approved for the treatment of patients with HER2-positive metastatic breast cancer in the third-line setting in the US as well as more than 50 countries. Additionally, it is approved by the FDA when used in combination with trastuzumab and capecitabine in adult patients with advanced unresectable or metastatic HER2-positive disease who received at least 1 prior HER2-based treatment in the metastatic setting in April 2020.3
“The positive results from HER2CLIMB-05, combined with [tucatinib’s] known safety profile in later-line settings, underscore its potential to play a meaningful role in front-line maintenance, where it may benefit a broader population of patients with [HER2-positive] disease,” Johanna Bendell, MD, chief development officer of Oncology at Pfizer, expressed in the news release.1 “We are grateful to the patients and investigators who contributed to this important research.”